Evidence map›Paper›PMID 40611150›Full record

ArticleBMC pulmonary medicine2025

An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer.

Yongfeng Yu, Fei Yao, Jin Wang, Zhan Huang, Tao Hu, Changbin Zhu, Shun Lu

Abstract read
In one paragraph

Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yongfeng YuDepartment of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241, Huaihai West Road, Shanghai, 200030, China.
Fei YaoDepartment of Medicine, Xiawei Medical Laboratory Co., Ltd, Shanghai, China.
Jin WangDepartment of Medicine, Xiawei Medical Laboratory Co., Ltd, Shanghai, China.
Zhan HuangDepartment of Medicine, Xiawei Medical Laboratory Co., Ltd, Shanghai, China.
Tao HuDepartment of Medicine, Xiawei Medical Laboratory Co., Ltd, Shanghai, China.
Changbin ZhuDepartment of Medicine, Xiawei Medical Laboratory Co., Ltd, Shanghai, China. changbin.zhu@amoydx.com.
Shun LuDepartment of Medical Oncology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, No. 241, Huaihai West Road, Shanghai, 200030, China. shunlu@sjtu.edu.cn.

Funding

Collaborative Innovation Center for Clinical and Translational Science by Ministry of Education & Shanghai TM202112, CCTS202204, CCTS202304National Multi-disciplinary Treatment Project for Major Diseases 2020NMDTPNational Natural Science Foundation of China 82030045, 82241227
6 · The paper itself

Abstract

backgroundEGFR mutations have been classified into four functional subgroups (Classical-like, P-loop and αC-helical compressing (PACC), T790M-like, and exon 20 loop insertions) based on their influence on EGFR protein structure, as well as response to various types of EGFR-tyrosine kinase inhibitors (TKIs). However, the differences in molecular phenotypes and clinical outcomes for patients carrying these different forms of EGFR mutations are not fully understood. Here we sought to investigate the distribution of different EGFR structural types in Chinese NSCLC patients and the biological characteristics of each subgroup.

methods2992 EGFR mutant NSCLC patients with available next-generation sequencing result were collected for mutation analysis. 118 patients with targeted RNA sequencing data were further analyzed to compare transcriptome differences across mutation subgroups.

resultsAcross the entire cohort, 80.82% of patients were Classical-like, 5.92% were PACC, 10.76% were T790M-like, and 2.51% were Ex20ins. TP53 was the most common co-occurring mutation across the four subgroups, occurring in 60% of the T790M-like subgroup. Interestingly, the Ex20ins group exhibited a notable proportion of genomic alterations related to DNA repair processes. Additionally, both the Ex20ins and T790M subgroups demonstrated higher tumor mutational burden (TMB) scores. Furthermore, for the first time, we observed transcriptomic heterogeneity within these four subgroups. Classical-like group displayed enrichment of immune-related pathways, including PD1 signaling, CD28 family, and TCR signaling. Notably, the L858R group showed significant enrichment in immune activation signatures, including effector memory CD8 T cells, natural killer cells, and MHC I/II. This suggests a potentially robust immune response in that group. In contrast, the T790M-like subgroups showed lower anti-tumor immune signatures but were marked by a significant enrichment in tumor proliferation signatures.

conclusionIn this study, we have employed a structure-based classification approach for EGFR mutants to comprehensively characterize the mutational landscape and heterogeneous biological traits at the transcriptional and functional levels in Chinese patients with NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAdultAgedChinaEast Asian PeopleErbB ReceptorsFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationProtein Kinase InhibitorsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsComprehensive profilingEGFRStructureSubtyping

Identifiers

PMID40611150
PMCPMC12224513

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.